[1] EUGENIA Z,MENG-YIN L,ANNE S，et al.T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells［J］.Cancer Immunology Research，2016，4(6)：498-508.
[2] MARKS DI,PAIETTA EM,MOORMAN AV，et al.T-cell acute lymphoblastic leukemia in adults:clinical features, immunophenotype,cytogenetics,and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)［J］.Blood，2009，114(25):5136-5145.
[3] GOLDBERG JM,SILVERMAN LB,LEVY DE，et al.Childhood T-cell acute lymphoblastic leukemia:the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience［J］.J Clin Oncol，2003，21(19):3616-3622.
[4] MAMONKIN M,ROUCE RH,TASHIRO H，et al.A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies［J］.Blood，2015，126(8):983-992.
[5] GOMES-SILVA D,SRINIVASAN M,SHARMA S，et al.CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies［J］.Blood，2017，130(3):285-296.
[6] MA G,SHEN J,PINZ K，et al.Targeting T cell malignancies using CD4CAR T-cells and implementing a natural safety switch［J］.Stem Cell Rev Rep，2019，15(3):443-447.
[7] DIEGO S,MATTEO LB,FRANCISCO G，et al.Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia［J］.Blood，2019，133(21):2291-2304.
[8] GUMBER D,WANG LD.Improving CAR-T immunotherapy:Overcoming the challenges of T cell exhaustion［J］.EBioMedicine，2022，77:103941.
[9] FUCHSL F,KRACKHARDT AM.Adoptive cellular therapy for multiple myeloma using CAR- and TCR-transgenic T cells:response and resistance［J］.Cells，2022，11(3)：410.
[10] ZHANG NH,CHEN X,ZHAO SS，et al.The expressional characteristics and diagnostic values of TRBC1 in mature T-cell lymphoma［J］.Chin J Hematol，2022，43(7):575-580.
[11] KAEWPREEDEE P,BOONRAT P,TANSIRI Y，et al.Dimorphism in the T-cell receptor constant region affects T-cell function, phenotype and HIV outcome［J］.AIDS，2019，33(9):1421-1429.
[12] BERG H,OTTESON GE,CORLEY H，et al.Flow cytometric evaluation of TRBC1 expression in tissue specimens and body fluids is a novel and specific method for assessment of T-cell clonality and diagnosis of T-cell neoplasms［J］.Cytometry B Clin Cytom，2021，100(3):361-369.
[13] RADVANYI LG,SHI Y,VAZIRI H，et al.CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response［J］.J Immunol，1996，156(5):1788-1798.
[14] NATARAJAN K,MCSHAN AC,JIANG J，et al.An allosteric site in the T-cell receptor Cβ domain plays a critical signalling role［J］.Nature Communications，2017，8:15260.
[15] KWOK M,RAWSTRON AC,VARGHESE A，et al.Minimal residual disease is an independent predictor for 10-year survival in CLL［J］.Blood，2016，128(24):2770.
[16] THEUNISSEN P,MEJSTRIKOVA E,SEDEK L，et al.Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia［J］.Blood，2016，129(3):347.
[17] GRIMWADE D,FREEMAN SD.Defining minimal residual disease in acute myeloid leukemia:which platforms are ready for "prime time"［J］.Hematology，2014（1）：222-233.
[18] KALEEM Z,CRAWFORD E,PATHAN MH，et al.Flow cytometric analysis of acute leukemias:Diagnostic utility and critical analysis of data［J］.Archives of Pathology & Laboratory Medicine，2003，127(1):42-48.
[19] HORNA MP,OTTESON GE,SHI MM，et al.Flow cytometric evaluation of surface and cytoplasmic TRBC1 expression in the differential diagnosis of immature T-cell proliferations［J］.American Journal of Clinical Pathology，2021，157（1）：64-72.
[20] 马耀坤,郑金娥,李小青，等.应用TRBC1鉴别T细胞克隆的研究［J］.临床血液学杂志,2023,36(04):260-264.
MA YK,ZHENG JE,LI XQ,et al.Identification of T cell clones by TRBC1［J］.J Clin Hematol(China),2023,36(04):260-264.
[21] 高梦鸽,常英军,赵晓甦.循环肿瘤DNA在淋巴瘤微小残留病检测中的应用［J］.临床荟萃,2019,34(05):467-471.
GAO MG,CHANG YJ,ZHAO XS.Application of circulating tumor DNA in the detection of minimal residual disease in lymphoma［J］.Clinical Focus，2019，34（05）：467-471.
[22] SHAO H,YUAN C M,XI L，et al.Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma［J］.Am J Clin Pathol，2010，133(4):592-601.
[23] NOEM M,MARGARIDA L,NEUS V，et al.Anti-TRBC1 antibody-based flow cytometric detection of T-cell clonality:standardization of sample preparation and diagnostic implementation［J］.Cancers，2021，13(17):4379.
[24] DUPUIS J,BOYE K,MARTIN N，et al.Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL):a new diagnostic marker providing evidence that AITL derives from follicular helper T cells［J］.American Journal of Surgical Pathology，2006，30(4):490.
[25] DORFMAN DM,BROWN JA,SHAHSAFAEI A，et al.Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma［J］.American Journal of Surgical Pathology，2006，30(7):802-810.
[26] ATTYGALLE A,AL-JEHANI R,DISS TC，et al.Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10［J］.Blood，2002，99(2):627-633.
[27] CHUNYAN W,LI Z,SONGYA L，et al.PD-1 combined with TRBC1 and pan-T cell antibodies for robustly monitoring angioimmunoblastic T-cell lymphoma［J］.Frontiers in Medicine，2022，9:62428.
[28] KERSHAW MH,WESTWOOD JA,DARCY PK.Gene-engineered T cells for cancer therapy［J］.Nat Rev Cancer，2013，13(8):525-541.
[29] LIM WA,JUNE CH.The principles of engineering immune cells to treat cancer［J］.Cell，2017，168(4):724-740.
[30] SRIVASTAVA S,RIDDELL SR.Engineering CAR-T cells:Design concepts［J］.Trends Immunol，2015，36(8):494-502.
[31] RESTIFO NP,DUDLEY ME,ROSENBERG SA.Adoptive immunotherapy for cancer:harnessing the T cell response［J］.Nat Rev Immunol，2012，12(4):269-281.
[32] GARDNER RA,FINNEY O,ANNESLEY C，et al.Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults［J］.Blood，2017，129(25):3322-3331.
[33] FRY TJ,SHAH NN,ORENTAS RJ，et al.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy［J］.Nat Med，2018，24(1):20-28.
[34] MACIOCIA PM, WAWRZYNIECKA PA, PHILIP B，et al. Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies［J］.Nat Med，2017，23(12):1416-1423.
[35] ZHANG C,PALASHATI H,RONG Z，et al.Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies［J］.Mol Cancer，2020，19(1):162.